PharmaRadar360

PharmaRadar360

OncologyDrug intelligence

Tagrisso

Osimertinib

EGFR tyrosine kinase inhibitor. Developed by AstraZeneca. Clinical, regulatory, and source evidence are connected below.

Company
AstraZeneca
Target / MOA
EGFR
Aliases
Tagrisso 路 AZD9291
Signals
21
Clinical trials
20
Approvals
1
Evidence sources
21

Latest signals

What changed

The three most recent source-backed changes linked to this drug.

clinical trialClinicalTrials.gov

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Phase 3 路 RECRUITING 路 NRG Oncology

clinical trialClinicalTrials.gov

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Phase 1 路 ACTIVE_NOT_RECRUITING 路 National Cancer Institute (NCI)

clinical trialClinicalTrials.gov

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Phase 3 路 RECRUITING 路 National Cancer Institute (NCI)

Clinical trials

Key active studies

A focused view of recently updated studies 路 20 linked records.

Phase 3RECRUITINGNCT05624996

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

NRG Oncology 路 Updated Apr 3, 2026

Phase 1ACTIVE NOT RECRUITINGNCT03831932

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

National Cancer Institute (NCI) 路 Updated Apr 3, 2026

Phase 3RECRUITINGNCT04181060

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

National Cancer Institute (NCI) 路 Updated Apr 3, 2026

Phase 2RECRUITINGNCT03191149

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

National Cancer Institute (NCI) 路 Updated Apr 3, 2026

Phase 2ACTIVE NOT RECRUITINGNCT06303167

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

National Cancer Institute (NCI) 路 Updated Apr 3, 2026

Phase 2ACTIVE NOT RECRUITINGNCT02465060

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI) 路 Updated Apr 3, 2026

Source evidence

Where this profile comes from

Facts link back to original registries, regulators, labels, and publishers. Counts change as source records update.

ClinicalTrials.govofficial 路 Latest Apr 3, 202620FDAofficial 路 Latest Apr 18, 20181
Professional referenceThis profile summarizes linked public evidence. It is not medical, legal, regulatory, or investment advice. Verify decisions against original sources.